Literature DB >> 29214524

Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.

Ahmed Reda1, Ann Van Schepdael2, Erwin Adams2, Prasanta Paul2, David Devolder3, Mohamed A Elmonem4,5, Koenraad Veys4,6, Ingele Casteels7, Lambertus van den Heuvel4,6,8, Elena Levtchenko4,6.   

Abstract

Cystinosis is a hereditary genetic disease that results in the accumulation of cystine crystals in the lysosomes, leading to many clinical manifestations. One of these manifestations is the formation of corneal cystine crystals, which can cause serious ocular complications. The only available drug to treat cystinosis is cysteamine, which breaks cystine and depletes its accumulation in the lysosomes. However, the oral form of cysteamine is not effective in treating corneal manifestations. Thus, ophthalmic solutions of cysteamine are applied. Because the commercial cysteamine eye drops are not available in most countries, hospital pharmacies are responsible for preparing "homemade" drops usually without a control of stability of cysteamine in different storage conditions. Hence, we aimed in this study to investigate the effect of different storage conditions on the stability of a cysteamine ophthalmic compounded solution. Cysteamine ophthalmic solution was prepared in the hospital pharmacy and sterilized using a candle filter. The preparations are then stored either in the freezer at -20°C or in the refrigerator at +4°C for up to 52 weeks. The amount of cysteamine hydrochloride in the preparation at different time points was determined using capillary electrophoresis (CE). Storage of the cysteamine ophthalmic preparations at +4° resulted in significant loss of free cysteamine at all time points, from 1 to 52 weeks of storage, when compared with storage in the freezer (-20°C). We demonstrate that cysteamine 0.5% compounded eye drops are easily oxidized within the first week after storage at +4°C, rendering the preparation less effective. Storage at -20°C is recommended to prevent this process.

Entities:  

Keywords:  Cysteamine; Cystinosis; Ophthalmic preparation

Year:  2017        PMID: 29214524      PMCID: PMC6226390          DOI: 10.1007/8904_2017_77

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  24 in total

1.  Clinical utility gene card for: cystinosis.

Authors:  Elena Levtchenko; Lambertus van den Heuvel; Francesco Emma; Corinne Antignac
Journal:  Eur J Hum Genet       Date:  2013-09-18       Impact factor: 4.246

2.  A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.

Authors:  Hong Liang; Antoine Labbé; Jeannie Le Mouhaër; Céline Plisson; Christophe Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-04-01       Impact factor: 4.799

3.  Recurrent crystal deposition after keratoplasty in nephropathic cystinosis.

Authors:  B Katz; R B Melles; J A Schneider
Journal:  Am J Ophthalmol       Date:  1987-08-15       Impact factor: 5.258

4.  Early occurrence of end-stage renal disease in a patient with infantile nephropathic cystinosis.

Authors:  H W Schnaper; J Cottel; S Merrill; E Marcusson; J M Kissane; G D Shackelford; S K So; R D Nelson; B R Cole; M L Smith
Journal:  J Pediatr       Date:  1992-04       Impact factor: 4.406

5.  Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.

Authors:  Albane Brodin-Sartorius; Marie-Josèphe Tête; Patrick Niaudet; Corinne Antignac; Geneviève Guest; Chris Ottolenghi; Marina Charbit; Dominique Moyse; Christophe Legendre; Philippe Lesavre; Pierre Cochat; Aude Servais
Journal:  Kidney Int       Date:  2011-09-07       Impact factor: 10.612

6.  A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis.

Authors:  M I Kaiser-Kupfer; M A Gazzo; M B Datiles; R C Caruso; E M Kuehl; W A Gahl
Journal:  Arch Ophthalmol       Date:  1990-05

7.  Mutational Spectrum of the CTNS Gene in Egyptian Patients with Nephropathic Cystinosis.

Authors:  Neveen A Soliman; Mohamed A Elmonem; Lambertus van den Heuvel; Rehab H Abdel Hamid; Mohamed Gamal; Inge Bongaers; Sandrine Marie; Elena Levtchenko
Journal:  JIMD Rep       Date:  2014-01-25

8.  CTNS mutations in an American-based population of cystinosis patients.

Authors:  V Shotelersuk; D Larson; Y Anikster; G McDowell; R Lemons; I Bernardini; J Guo; J Thoene; W A Gahl
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

9.  Hereditary disorders in Saguenay-Lac-St-Jean (Quebec, Canada).

Authors:  M De Braekeleer
Journal:  Hum Hered       Date:  1991       Impact factor: 0.444

10.  A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.

Authors:  F Iwata; E M Kuehl; G F Reed; L M McCain; W A Gahl; M I Kaiser-Kupfer
Journal:  Mol Genet Metab       Date:  1998-08       Impact factor: 4.797

View more
  3 in total

1.  The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series.

Authors:  Susmito Biswas; Krishanthy Sornalingam
Journal:  Ophthalmol Ther       Date:  2018-12-05

2.  Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis.

Authors:  Freya Peeters; Catherine Cassiman; Karel Van Keer; Elena Levtchenko; Koenraad Veys; Ingele Casteels
Journal:  Ophthalmol Ther       Date:  2019-09-27

3.  Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations.

Authors:  Cristina Martín-Sabroso; Mario Alonso-González; Ana Fernández-Carballido; Juan Aparicio-Blanco; Damián Córdoba-Díaz; Federico Navarro-García; Manuel Córdoba-Díaz; Ana I Torres-Suárez
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.